Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Rachel A. Nieto, William James Deardorff & George T. Grossberg. (2016) Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer’s disease. Expert Opinion on Pharmacotherapy 17:6, pages 861-870.
Read now
Read now
Han-Chang Huang, Di Tang, Ke Xu & Zhao-Feng Jiang. (2014) Curcumin attenuates amyloid-β-induced tau hyperphosphorylation in human neuroblastoma SH-SY5Y cells involving PTEN/Akt/GSK-3β signaling pathway. Journal of Receptors and Signal Transduction 34:1, pages 26-37.
Read now
Read now
Serge Gauthier, Alain Robillard, Sharon Cohen, Sandra Black, John Sampalis, Diane Colizza, Frederica de Takacsy & Robyn Schecter. (2013) Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE study. Current Medical Research and Opinion 29:8, pages 989-1000.
Read now
Read now
Paul T Francis, Chris G Parsons & Roy W Jones. (2012) Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer’s disease. Expert Review of Neurotherapeutics 12:11, pages 1351-1365.
Read now
Read now
Daphne Lo & George T Grossberg. (2011) Use of memantine for the treatment of dementia. Expert Review of Neurotherapeutics 11:10, pages 1359-1370.
Read now
Read now
Articles from other publishers (39)
Hui Yue, Hong-rui Bao, Yan-yin Cui, Wen-xin Hou & Hong-juan Wen. 2024. Computational and Experimental Simulations in Engineering. Computational and Experimental Simulations in Engineering
1211
1222
.
Shanquan Chen, Annabel C. Price, Rudolf N. Cardinal, Sinéad Moylett, Anne D. Kershenbaum, James Fitzgerald, Christoph Mueller, Robert Stewart & John T. O’Brien. (2022) Association between antidementia medication use and mortality in people diagnosed with dementia with Lewy bodies in the UK: A retrospective cohort study. PLOS Medicine 19:12, pages e1004124.
Crossref
Crossref
Ekta Shirbhate, Vijay K. Patel, Priya Tiwari, Rakesh Kore, Ravichandran Veerasamy, Achal Mishra & Harish Rajak. (2022) Combination Therapy for the Treatment of Alzheimer’s Disease: Recent
Progress and Future Prospects. Current Topics in Medicinal Chemistry 22:22, pages 1849-1867.
Crossref
Crossref
Rouchan Ali, Ghanshyam Das Gupta & Pooja A. Chawla. (2022) Aducanumab: A new hope in Alzheimer's disease. Health Sciences Review 4, pages 100039.
Crossref
Crossref
Adrian L. Knorz & Arnim Quante. (2021) Alzheimer’s Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review. Journal of Geriatric Psychiatry and Neurology 35:4, pages 475-486.
Crossref
Crossref
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
231
269
.
Susan Tomczak Matthiesen, Sophie Rosenkjær, Moa Pontén, Karin B. Jensen, Hanne Gottrup & Lene Vase. (2021) Does Certainty of Genuine Treatment Increase the Drug Response in Alzheimer’s Disease Patients: A Meta-Analysis and Critical Discussion1. Journal of Alzheimer's Disease 84:4, pages 1821-1832.
Crossref
Crossref
HyunChul Youn, Kang Joon Lee, Shin-Gyeom Kim, Seong-Jin Cho, Woo Jung Kim, Won Joon Lee, Jae Yeon Hwang, Changsu Han, Cheolmin Shin & Han-yong Jung. (2021) The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer’s Dementia: A Double-Blind Randomized Placebo-Controlled Trial. Psychiatry Investigation 18:3, pages 233-240.
Crossref
Crossref
Tingting Zhang, Nanyang Liu, Hongfu Cao, Wei Wei, Lina Ma & Hao Li. (2020) Different Doses of Pharmacological Treatments for Mild to Moderate Alzheimer’s Disease: A Bayesian Network Meta-Analysis. Frontiers in Pharmacology 11.
Crossref
Crossref
Md. Tanvir Kabir, Md. Sahab Uddin, Abdullah Al Mamun, Philippe Jeandet, Lotfi Aleya, Rasha A. Mansouri, Ghulam Md Ashraf, Bijo Mathew, May N. Bin-Jumah & Mohamed M. Abdel-Daim. (2020) Combination Drug Therapy for the Management of Alzheimer’s Disease. International Journal of Molecular Sciences 21:9, pages 3272.
Crossref
Crossref
Carrie D. Patnode, Leslie A. Perdue, Rebecca C. Rossom, Megan C. Rushkin, Nadia Redmond, Rachel G. Thomas & Jennifer S. Lin. (2020) Screening for Cognitive Impairment in Older Adults. JAMA 323:8, pages 764.
Crossref
Crossref
Sergio del Río-Sancho. 2020. Diagnosis and Management in Dementia. Diagnosis and Management in Dementia
511
527
.
Park, Park, Na, Hiroyuki, Kim, Jung, Kim & Park. (2019) Combined Intervention of Physical Activity, Aerobic Exercise, and Cognitive Exercise Intervention to Prevent Cognitive Decline for Patients with Mild Cognitive Impairment: A Randomized Controlled Clinical Study. Journal of Clinical Medicine 8:7, pages 940.
Crossref
Crossref
Steve Pedrini, Mike Morici & Ralph N. Martins. 2019. Neurodegeneration and Alzheimer's Disease. Neurodegeneration and Alzheimer's Disease
391
442
.
Alireza Atri. (2019) The Alzheimer’s Disease Clinical Spectrum. Medical Clinics of North America 103:2, pages 263-293.
Crossref
Crossref
George T. Grossberg, Gary Tong, Anna D. Burke & Pierre N. Tariot. (2019) Present Algorithms and Future Treatments for Alzheimer’s Disease. Journal of Alzheimer's Disease 67:4, pages 1157-1171.
Crossref
Crossref
Kelvin K.F. Tsoi, Joyce Y.C. Chan, Felix C.H. Chan, Hoyee W. Hirai, Timothy C.Y. Kwok & Samuel Y.S. Wong. (2018) Monotherapy Is Good Enough for Patients With Mild‐to‐Moderate Alzheimer's Disease: A Network Meta‐Analysis of 76 Randomized Controlled Trials. Clinical Pharmacology & Therapeutics 105:1, pages 121-130.
Crossref
Crossref
Jaume Folch, Oriol Busquets, Miren Ettcheto, Elena Sánchez-López, Ruben Dario Castro-Torres, Ester Verdaguer, Maria Luisa Garcia, Jordi Olloquequi, Gemma Casadesús, Carlos Beas-Zarate, Carme Pelegri, Jordi Vilaplana, Carme Auladell & Antoni Camins. (2018) Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. Journal of Alzheimer's Disease 62:3, pages 1223-1240.
Crossref
Crossref
Jordi Olloquequi, Elizabeth Cornejo-Córdova, Ester Verdaguer, Francesc X Soriano, Octavio Binvignat, Carme Auladell & Antoni Camins. (2018) Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications. Journal of Psychopharmacology 32:3, pages 265-275.
Crossref
Crossref
Jeong Jin Park, Seong Hye Choi, SangYun Kim, Ae Young Lee, So Young Moon, Jun Hong Lee, Jae Cheol Kwon, Kyung Won Park, Bon D. Ku, Hyun Jeong Han, Eun‐Joo Kim & Yong S. Shim. (2016) Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease. Geriatrics & Gerontology International 17:10, pages 1661-1666.
Crossref
Crossref
Taro Kishi, Shinji Matsunaga, Kazuto Oya, Ikuo Nomura, Toshikazu Ikuta & Nakao Iwata. (2017) Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis. Journal of Alzheimer's Disease 60:2, pages 401-425.
Crossref
Crossref
Kyung Won Park, Eun-Joo Kim, Hyun Jeong Han, Yong S. Shim, Jae C. Kwon, Bon D. Ku, Kee Hyung Park, Hyon-Ah Yi, Kwang K. Kim, Dong Won Yang, Ho-Won Lee, Heeyoung Kang, Oh Dae Kwon, SangYun Kim, Jae-Hyeok Lee, Eun Joo Chung, Sang-Won Park, Mee Young Park, Bora Yoon, Byeong C. Kim, Sang Won Seo & Seong Hye Choi. (2017) Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer’s dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial. PLOS ONE 12:8, pages e0182123.
Crossref
Crossref
Soo J Yoon, Seong H Choi, Hae R Na, Kyung-Won Park, Eun-Joo Kim, Hyun J Han, Jae-Hong Lee, Young S Shim & Duk L Na. (2017) Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine. Geriatrics & Gerontology International 17:3, pages 494-499.
Crossref
Crossref
Yasushi Yabuki, Kazuya Matsuo, Koga Hirano, Yasuharu Shinoda, Shigeki Moriguchi & Kohji Fukunaga. (2017) Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice. Pharmacology 99:3-4, pages 160-171.
Crossref
Crossref
R. Haussmann & M. Donix. (2016) Memantin als Add-on-Medikation zur Acetylcholinesteraseinhibitor-Therapie bei Alzheimer-DemenzMemantine as add-on medication to acetylcholinesterase inhibitor therapy for Alzheimer dementia. Der Nervenarzt 88:1, pages 40-45.
Crossref
Crossref
Kelvin K.F. Tsoi, Joyce Y.C. Chan, Michael P.F. Wong & Timothy C.Y. Kwok. (2016) Response to the Letter to the Editor by Shinji Matsunaga “Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials”. Journal of the American Medical Directors Association 17:11, pages 1063.
Crossref
Crossref
Shinji Matsunaga, Taro Kishi & Nakao Iwata. (2016) Tsoi KK et al: Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials. Journal of the American Medical Directors Association 17:11, pages 1061-1062.
Crossref
Crossref
Kelvin K.F. Tsoi, Joyce Y.C. Chan, Nelson W.Y. Leung, Hoyee W. Hirai, Samuel Y.S. Wong & Timothy C.Y. Kwok. (2016) Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials. Journal of the American Medical Directors Association 17:9, pages 863.e1-863.e8.
Crossref
Crossref
Bernd Ibach. 2016. Polypharmazie in der Behandlung psychischer Erkrankungen. Polypharmazie in der Behandlung psychischer Erkrankungen
163
186
.
Oliver Peters, Manuel Fuentes, Lisa Katharina Joachim, Frank Jessen, Christian Luckhaus, Johannes Kornhuber, Johannes Pantel, Michael Hüll, Klaus Schmidtke, Eckart Rüther, Hans-Jürgen Möller, Alexander Kurz, Jens Wiltfang, Wolfgang Maier, Birgitt Wiese, Lutz Frölich & Isabella Heuser. (2015) Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 1:3, pages 198-204.
Crossref
Crossref
Radoslaw Magierski & Tomasz Sobow. (2015) Benefits and risks of add-on therapies for Alzheimer's disease. Neurodegenerative Disease Management 5:5, pages 445-462.
Crossref
Crossref
William James Deardorff, Eliahu Feen & George T. Grossberg. (2015) The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease. Drugs & Aging 32:7, pages 537-547.
Crossref
Crossref
R. Schmidt, E. Hofer, F. H. Bouwman, K. Buerger, C. Cordonnier, T. Fladby, D. Galimberti, J. Georges, M. T. Heneka, J. Hort, J. Laczó, J. L Molinuevo, J. T. O'Brien, D. Religa, P. Scheltens, J. M. Schott & S. Sorbi. (2015) EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. European Journal of Neurology 22:6, pages 889-898.
Crossref
Crossref
Shinji Matsunaga, Taro Kishi & Nakao Iwata. (2015) Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis. International Journal of Neuropsychopharmacology 18:5.
Crossref
Crossref
Hae Ri NaMoon Ho ParkSangYun KimDong Won YangSeong-Hye ChoiHyun Duk YangYoungSoon YangHyun Jeong HanJung Seok LeeYoung-Chul YoonSeong-Ho KohJung Eun KimBon D. KuHee-Jin KimKyung Won ParkEun-Joo KimBora YoonKey Jung Park. (2015) Factors Influencing Skin Tolerability to the Rivastigmine Patch in Patients with Alzheimer's Disease. Dementia and Neurocognitive Disorders 14:1, pages 31.
Crossref
Crossref
Hyun Jeong Han, Jay C. Kwon, Jung Eun Kim, Shin Gyeom Kim, Jong-Moo Park, Kyung Won Park, Key Chung Park, Kee Hyung Park, So Young Moon, Sang Won Seo, Seong Hye Choi & Soo-Jin Cho. (2015) Effect of Rivastigmine or Memantine Add-on Therapy Is Affected by Butyrylcholinesterase Genotype in Patients with Probable Alzheimer's Disease. European Neurology 73:1-2, pages 23-28.
Crossref
Crossref
Andrea C. Paula-Lima, Jordano Brito-Moreira & Sergio T. Ferreira. (2013) Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease. Journal of Neurochemistry 126:2, pages 191-202.
Crossref
Crossref
Serge Gauthier & José L. Molinuevo. (2012) Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease. Alzheimer's & Dementia 9:3, pages 326-331.
Crossref
Crossref
Hyun Jeong Han, Byeong C. Kim, Jun-Young Lee, Seung-Ho Ryu, Hae Ri Na, Soo Jin Yoon, Hyun Young Park, Joon Hyun Shin, Soo-Jin Cho, Hyon-Ah Yi, Mun Seong Choi, Jae-Hyeok Heo, Kyung Won Park, Kwang K. Kim & Seong Hye Choi. (2012) Response to Rivastigmine Transdermal Patch or Memantine plus Rivastigmine Patch is affected by Apolipoprotein E Genotype in Alzheimer Patients. Dementia and Geriatric Cognitive Disorders 34:3-4, pages 167-173.
Crossref
Crossref